APA (7th ed.) Citation

JL, B., AB, B., I, S., JM, M., A, P., JA, G. E., . . . RF, D. (2023). Transfusion-associated adverse events incidence and severity after the implementation of an active hemovigilance program with 24 h follow-up. A prospective cohort study. Transfusion, 63(10), 1859. https://doi.org/10.1111/trf.17538

Chicago Style (17th ed.) Citation

JL, Bueno, et al. "Transfusion-associated Adverse Events Incidence and Severity After the Implementation of an Active Hemovigilance Program with 24 h Follow-up. A Prospective Cohort Study." Transfusion 63, no. 10 (2023): 1859. https://doi.org/10.1111/trf.17538.

MLA (9th ed.) Citation

JL, Bueno, et al. "Transfusion-associated Adverse Events Incidence and Severity After the Implementation of an Active Hemovigilance Program with 24 h Follow-up. A Prospective Cohort Study." Transfusion, vol. 63, no. 10, 2023, p. 1859, https://doi.org/10.1111/trf.17538.